Stemline Therapeutics, a clinical-stage biopharmaceutical company developing novel oncology therapeutics, and The Leukemia & Lymphoma Society (LLS) are collaborating to accelerate the development of SL-401 for the treatment of acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare hematological disorder with both leukemic and lymphomatous characteristics.

LLS has committed over $3 million to support this effort and has provided a comprehensive educational program to increase physician and patient awareness of BPDCN.

SL-401, a novel targeted therapy directed to cancer stem cells (CSCs) and tumor bulk, has demonstrated efficacy in patients with advanced AML and BPDCN. This includes multiple durable complete responses (CRs) in both indications, a greater than 80% overall response rate (ORR) in BPDCN to date and a notable improvement in overall survival (OS) of third-line AML patients relative to historical data.